Advances in gene therapy for EB, such as Beremagene geperpavec (B-VEC) for dystrophic EB and ex vivo LAMB3 correction for JEB (18), provide a rationale for developing ITGB4-targeting strategies, in line with recent insights into ITGB4 genetics and management (19). This evidence concerns the gene LAMB3 and epidermolysis bullosa.